On July 17, CARsgen Therapeutics-B fell 6.03% in regular trading, trading at HK$15.98/share, with turnover of approximately HK$16.93 million. The decline came amid a broad sell-off across the biotechnology sector.

The biotech industry where CARsgen belongs experienced widespread weakness. Among sector constituents, Akeso dropped 8.94%, 3SBio fell 7.59%, SKBioscience declined 3.64%, Innovent Biologics shed 2.97%, and BeiGene retreated 2.36%. The broad-based nature of the decline suggests sector-level selling pressure rather than company-specific negative developments.

Notably, CARsgen had gained over 6% on July 15 and surged more than 7% on July 16 following positive clinical data showing its CAR-T therapy Satri-Cel demonstrated zero post-surgical recurrence or metastasis in a gastric cancer consolidation treatment trial accepted for poster presentation at ESMO, along with news that the product passed preliminary review for a commercial insurance innovative drug catalog. The current pullback appears to reflect profit-taking and sector rotation following the recent run-up.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)